November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Article of the day, August 30th, suggested by the Immune Oncology Research Institute
Aug 30, 2024, 10:39

Article of the day, August 30th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Authors: Georgina V Long, Jason J Luke, Prof Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Prof Piotr Rutkowski, Francesco Spagnolo, Prof Jacek Mackiewicz, Vanna Chiarion-Sileni, John M Kirkwood, Caroline Robert, Prof Jean-Jacques Grob, Federica de Galitiis, Prof Dirk Schadendorf, Matteo S Carlino, Peter Mohr, Reinhard Dummer, Jeffrey E Gershenwald, Charles H Yoon, Xi Lawrence Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Prof Alexander M M Eggermont and Paolo A Ascierto.

Article of the day, August 30th, suggested by the Immune Oncology Research Institute

Author Affiliations: Melanoma Institute Australia ,Royal North Shore Hospital ,UPMC ,IDI IRCCS – Istituto Dermopatico dell’Immacolata ,Western Sydney Local Health District ,Elbe Kliniken Stade-Buxtehude GmbH ,MD Anderson Cancer Center ,CCC München – Comprehensive Cancer Center München ,et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.